Statera Biopharma Statistics
Share Statistics
Statera Biopharma has 71.42M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 71.42M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 774.53K, so undefined% of the outstanding
shares have been sold short.
| Short Interest | 774.53K |
| Short % of Shares Out | n/a |
| Short % of Float | 1.61% |
| Short Ratio (days to cover) | 0.39 |
Valuation Ratios
The PE ratio is -0.46 and the forward
PE ratio is null.
Statera Biopharma's PEG ratio is
0.
| PE Ratio | -0.46 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -51.5 |
| P/FCF Ratio | -2.85 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Statera Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37,
with a Debt / Equity ratio of -10.37.
| Current Ratio | 0.37 |
| Quick Ratio | 0.37 |
| Debt / Equity | -10.37 |
| Debt / EBITDA | 0.42 |
| Debt / FCF | -0.57 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,791,481.83 |
| Employee Count | 46 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 72.53M |
| Effective Tax Rate | -71.2% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is -4.78, so Statera Biopharma's
price volatility has been lower than the market average.
| Beta | -4.78 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0 |
| Relative Strength Index (RSI) | 48.12 |
| Average Volume (20 Days) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -488.31K |
| Operating Income | -98.34M |
| Net Income | -174.41M |
| EBITDA | 38.93M |
| EBIT | -170.9M |
| Earnings Per Share (EPS) | -4.97 |
Full Income StatementBalance Sheet
The company has 1.84M in cash and 16.26M in
debt, giving a net cash position of -14.42M.
| Cash & Cash Equivalents | 1.84M |
| Total Debt | 16.26M |
| Net Cash | -14.42M |
| Retained Earnings | -129.48M |
| Total Assets | 12.75M |
| Working Capital | -21.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -28.19M
and capital expenditures -182.97K, giving a free cash flow of -28.38M.
| Operating Cash Flow | -28.19M |
| Capital Expenditures | -182.97K |
| Free Cash Flow | -28.38M |
| FCF Per Share | -0.81 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
